Historical Background to StratCan, forerunner to Cancer Research KI

The Strategic Research Area StratCan was in 2019 merged with the organisation KICancer into one organisation with the name Cancer Research KI. Cancer Research KI aims to expand the existing strength in cancer biology at Karolinska Institutet (KI), by supporting high impact research projects, promising young researchers and required infrastructure.

Cancer Research KI (former StratCan) research 2015-19

StratCan  Executive Board members are appointed by the KI Dean of research. The members are selected to represent different areas of expertise and to be based at different departments on both campuses in order to cover most of the large cancer research field at KI:

StratCan Executive Board 2016-19 research focus

Jonas Bergh, StratCan Research KI (Onk-Pat), research: Breast Cancer

Kamila Czene, Co-Director StratCan (MEB, Deputy Dean), research: Etiology of breast cancer

Martin Bergö (BioNut), research: Antioxidants and cancer

Eva Hellström-Lindberg (MedH, Director HERM), research: Myelodysplastic syndromes (MDS)

Lars Holmgren (Onk-Pat, Deputy Dean), research: Mechanisms of blood vessel formation

Randall Johnson (CMB), research: Hypoxia in physiological and pathological contexts

Olli Kallioniemi (Onk-Pat, Director SciLifeLab), research: Precision Cancer Medicine

Sonia Lain (MTC), research: Tumor selective compounds

Andreas Lundqvist (Onk-Pat), research: Cell based immunotheraphy for cancer

Anna Martling (MMK), research: Colorectal cancer and surgery

Ingemar Ernberg (MTC, Director KICancer) affiliated member, field: Cancer and infections

Cancer Researchers at KI and their research areas

StratCan research environment 2010-14

The research themes and original 10 applicant research groups included in the application for funding of the Strategic Research Area are listed below (StratCan was initially called Center for Integrated Cancer Studies at Karolinska Institutet, CICS-KI). StratCan received excellent evaluation for its first 5-years (2010-2014) and was granted funding by the Swedish government for another 5-year period (2015-2019), 20 MSEK/ year.

1. Prevention and early detection
2. Functional annotation of genomic data
3. Tumor microenvironment
4. Targeted therapy and personalized medicine

The environment has since start been complemented with receivers of StratCan grants and positions. StratCan has increased in size as has the scientific output including number of publications in international leading journals in the field.

Applicant Research Groups StratCan 2010-2014

Jonas Bergh, Breast cancer translational research studies

Christer Betsholtz, Vascular biology research

Henrik Grönberg, Prostate cancer and new biomarkers

Catharina Larsson, Disease development on the molecular level

Hans-Gustav Ljunggren, NK cells in health and disease

Rolf Ohlsson, Epigenome and cancer

Rune Toftgård, Hedgehog signalling in embryonic development and cancer

Jussi Taipale, Cell cycle progression and transcriptional regulation of cell growth

Klas Wiman, Tumor suppressor p53 and novel anti-cancer drugs

Arne Östman, Tumor stroma and protein tyrosine phosphatases

Associated Cancer Centers at KI

IMTAC, Director Rolf Kiessling

BRECT, Director Jonas Bergh

ACT, Director Galina Selivanova

STARGET, Director Arne Östman

CRisP, Director Henrik Grönberg